Drug
Gd2 Sada And 177lu Dota
Gd2 Sada And 177lu Dota: highest development phase Phase 1, developed by Y-mAbs Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi) NCT05130255 | Phase 1 | SCLC |
Latest
No recent events.
Follow Gd2 Sada And 177lu Dota on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.